Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04147819
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
Overview
In this study, we want to learn how safe and effective the study drug, BAY2701439, is in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor Receptor 2) and cannot be cured by currently available treatment options.
Drug / Compound
Isotope(s):
THORIUM-227
Radioisotope: Th-227
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 19 Days
Decay Mode: ALPHA, BETA
Energy: Alpha 5.9 MeV (Ra223), 5.7 MeV ( Rn219), Total 5 Alpha particles (Total 34MeV)
Range: <0.1 mm
Decay Daughters: Ra223, Rn219, Po215, Pb211, Bi211, Tl207 Pb207 (Stable)
Status: Clinical Trials Only
Target(s):
Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Share your feedback
Help us improve your experience